Drug intelligence / Profile preview

Zonuron-T

Development stage: Unknown
Lead developer: Zota Pharmaceuticals
Modality: Small Molecules
Administration: Oral

Overview

Zonuron-T is a combination nutritional supplement and therapeutic formulation developed by Zota Health Care. It contains methylcobalamin (1500 mcg), the neurologically active form of vitamin B12, and folic acid (5 mg). The product is recognized as a novel formulation by the developer, who has patented specific delivery methods including an oral liquid spray and tablets to improve bioavailability and patient adherence. Zonuron-T is primarily indicated for the treatment of peripheral neuropathy, diabetic neuropathy, megaloblastic anemia, and vitamin B12 deficiency. By providing essential cofactors for methionine synthesis and DNA production, it supports nerve regeneration and red blood cell maturation.

Brand names: Zonuron-T

Targets

DHFR (Dihydrofolate reductase)MTR (Methionine synthase)

Beyond the preview

Go deeper on Zonuron-T.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zonuron-T.

Explore the full profile